Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Vaccine. Author manuscript; available in PMC 2010 October 30.
Published in final edited form as:
PMCID: PMC2767427

Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity


Recombinant Adenovirus serotype 5 (Ad5) vectors have been used as vaccine platforms in numerous animal and human clinical studies. The immune response induced by Ad5 vaccines can be mitigated due to pre-existing Ad5 immunity. We report here the use of a novel Ad5 platform to induce cellular immune responses (CMI) in Ad5 hyper immunized mice. The effectiveness of the Ad5 [E1−, E2b−] vaccine platform was evaluated using HIV-1 Gag, Pol, and Nef as antigenic transgenes. Broad CMI was induced following vaccination with the HIV-1 expressing vectors in Ad5 naïve and Ad5 immunized mice. A mixture of the three vaccines induced CMI against each transgene product even in the presence of hyper Ad5 immunity.

Keywords: Adenovirus, vaccine, Ad5-immunity, HIV-1


The level of cell mediated immunity (CMI) generated by infection or immunization correlates with protection against certain disease progression (1, 2). This may be the case because a robust CMI response suppresses viral replication as a result of infected cell destruction and subsequently may prevent the emergence of mutant viruses as well. Live viral vectors, including those based on Adenovirus (Ad), modified vaccinia virus Ankara (MVA), canarypox, vesicular stomatitis virus, herpes virus and others, have been reported to elicit protective CMI responses (3,4). Among the cadre of vectors, Ad serotype 5 (Ad5) appears to have a number of advantages including the ability to induce mucosal immunity (5), direct infection of antigen-presenting dendritic cells (6,7), induction of 5–10 fold greater CMI response than MVA and others (8, 9), higher protective effectiveness on a per-cytotoxic T cell basis (10) and are well tolerated in human vaccinees (10,11).

Current generation Ad5 vectors utilized are deleted at the E1 and E3 or the E1, E3 and E4 regions (Ad5 [E1−]). Ad5 immunity has been shown to suppress the immunogenicity of Ad5 [E1−] vaccines in both preclinical studies and clinical trials (8, 1214). This is a challenge due to the presence of Ad5 immunity in a high percentage of potential vaccinees due to natural infection (15). Investigators have proposed overcoming Ad5 immunity by using different Ad serotypes under the assumption that pre-existing vector specific immunity in the general population would not be as prevalent as it is to Ad5. An important issue with this technique is that once a vaccinee is immunized with an alternative serotype, a serotype specific immune response will be mounted. One cannot then administer a further re-immunization (boost) with that vaccine or use that viral backbone to vaccinate against a different antigen; therefore, terminating the future use of that alternative Ad vector in the vaccinee.

A uniquely modified Ad5 vector with deletion of the E2b region encoding viral DNA polymerase (pol) and the pre-terminal protein (pTP) genes (Ad5 [E1−, E2b−]) has been used to improve gene therapies (16, 17). This modification results in dramatic reduction of Ad5 late gene expression (16), which leads to increased quantity of stable transgene expression in a number of animal models (18,19) and reduced acute toxicities as compared to Ad5 [E1−] vectors (20,21). Minimizing Ad5 viral protein expression may reduce the potential of Ad5 viral proteins from impacting host immune responses. We constructed Ad5 [E1−, E2b−] vectors expressing the HIV-1 Gag, Pol, and Nef genes as “target” antigens. Studies were performed to assess the propensity of the novel Ad5 [E1−, E2b−] vector to induce CMI responses in an Ad5 naïve and an Ad5 immune murine model. We found that the novel Ad5 [E1−, E2b−] viral vector can induce both a high frequency and a broad range of HIV-1 Gag, Pol, and Nef specific CMI responses following immunization despite the presence of Ad5 immunity.


2.1 Vaccine Vectors

Using the HXB Gag, NL4-3 Pol and Nef genes (Genbank Accession # K03455 for Gag, M19921 for Pol and Nef) derived from VRC-4401, VRC-4409, and VRC-4404, respectively (kindly provided by the Vaccine Research Center, NIAIDs, NIH), the Ad5 [E1−, E2b−]-gag, Ad5 [E1−, E2b−]-pol, and Ad5 [E1−, E2b−]-nef vectors were constructed, and vaccines were produced and purified according to previously described procedures (16).

2.2 Animals

Specific pathogen-free, female BALB/c mice (Jackson Laboratory, Bar Harbor, Maine) ages 6 to 8 weeks were housed in animal facilities at the Infectious Disease Research Institute (Seattle, Washington) and all procedures were conducted according to IACUC approved protocols.

2.3 Immunization schedule

Ad5 naïve mice (n=5/group) were immunized intradermally three times at two week intervals with 1010 VP of Ad5 [E1−, E2b−]-gag, Ad5 [E1−, E2b−]-pol, or Ad5 [E1−, E2b−]-nef separately, or all three vaccines simultaneously for triad vaccination. To develop Ad5 immune mice, naïve mice were immunized twice with 1010 VP of Ad5 [E1−]-null (an Ad5 [E1−] vector with no insert) at a two-week interval. As previously determined, two immunizations with 1010 VP Ad5 [E1−]-null induces an Ad5 neutralizing antibody titer of approximately 1:200. Fourteen days following the second Ad5 [E1−]-null immunization, mice were immunized three times at 14-day intervals with 1010 VP of Ad5 [E1−, E2b−]-gag, Ad5 [E1−, E2b−]-pol, or Ad5 [E1−, E2b−]-nef. For the triad immunization protocol a mixture of 1010 VP of each of the vaccines was used. Control mice were injected with injection buffer (20 mM HEPES with 3% sucrose) alone. Fourteen days after the final immunization splenocytes from all mice were assessed by ELISpot assay for the secretion of IFN-γ and IL-2.

2.4 Adenovirus Neutralization Assay

Dilutions of heat inactivated test sera in 100 μL DMEM containing 10% fetal bovine serum were mixed with 4 × 1010 VP of Ad5 [E1−]-null and incubated for 60 minutes. Then the samples were added to microwells containing the HEK-293 cells at 2 × 103 cells/well and incubated for an additional 72 hours. An MTT reduction assay was used to quantify resultant cell killing, and endpoint Ad5 NAb titers were then determined.

2.5 Enzyme-Linked Immunospot (ELISpot) Assay

An ELISpot assay was used to detect HIV-1 Gag, Pol and Nef specific IFN-γ and IL-2–producing T cells from mouse splenocytes stimulated with Gag, Pol or Nef peptides (provided by the NIH AIDS Research and Reference Reagent Program). The ELISpot assay was run according to the manufacture’s protocols (eBioscience, San Diego, CA). Splenocytes were used at a concentration of 2 × 105 cells/well and reported as the number of spots per 106 cells per well. HIV-1 peptides were utilized at 0.2 μg of each peptide/well. Cells stimulated with concanavalin A (ConA) at a concentration of 0.0625 μg/well served as a positive control. Colored spot-forming cells (SFC) were counted using an Immunospot ELISpot plate reader (Cellular Technology, Shaker Heights, OH) and responses were considered to be positive if, 1) 50 SFC were detected/106 cells after subtraction of the negative control and, 2) SFC were ≥2-fold than those in the negative control wells. SFC quantities are reported as the number of observed spots per 106 cells per well.

To map the breadth of the HIV-1 specific CMI response Gag, Pol and Nef pools consisting of 15 amino acid peptides with an 11-mer overlap were used to stimulate splenocytes. Peptide pools (PP) consisted of the following: 4 Gag PP with 31 peptides/pool spanning the entire gag protein and 5 Pol PP with 50 peptides/pool spanning the entire Pol protein.

2.6 Statistical analysis

Statistically significant differences in the mean CMI responses between groups of animals were determined by Student’s t-test with a p-value of 0.05 or lower being considered significant, using GraphPad PrismR (GraphPad Software, Inc.).


3.1 CMI responses to immunization in Ad5 naïve mice

The immunogenicity of homologous vaccination in naïve mice was determined following three immunizations with Ad5 [E1−, E2b−]gag, Ad5 [E1−, E2b−]-pol, or Ad5 [E1−, E2b−]-nef. Splenocytes were collected 14 days after the final immunization and assessed by ELISpot to determine Gag, Pol, or Nef-specific IFN-γ and IL-2 secretion. The IFN-γ transgene-specific response was highest to Pol (6717 ± 376 SFC/106 splenocytes) and was also robust to Gag (432 ± 157 SFC/106 splenocytes) and Nef (578 ± 123 SFC/106 splenocytes). Transgene-specific IL-2 secretion was detected at high levels in Pol-immunized mice (1021 ± 122 SFC/106 splenocytes) and response to Gag-immunization (93 ± 22 SFC/106 splenocytes) and Nef-immunization (46 ± 9 SFC/106 splenocytes) was also recorded. These data confirm that Ad5 [E1−, E2b−]-gag, Ad5 [E1−, E2b−]-pol, and Ad5 [E1−, E2b−]-nef vaccines induce specific CMI responses in Ad5 naïve mice.

3.2 CMI responses to immunization in Ad5 immune mice

HIV-1 transgene specific CMI responses following three immunizations with Ad5 [E1−, E2b−]-gag, Ad5 [E1−, E2b−]-pol, or Ad5 [E1−, E2b−]-nef was determined in Ad5 immune mice (mice were pre-immunized twice with Ad5 [E1−]-null). Fourteen days after the third vaccination splenocytes were assessed by ELISpot to determine the number of splenocytes secreting IFN-γ and IL-2. Transgene-specific IFN-γ secretion to Gag (263 ± 23 SPC/106 splenocytes) and Pol (2406 ± 304 SFC/106 splenocytes) as well as IL-2 specific secretion to Gag (73 ± 2 SFC/106 splenocytes) and Pol (305 ± 69 SFC/106 splenocytes were detected despite the presence of Ad5 immunity. Ad5 [E1−, E2b−]-nef also induced a measurable level of Nef specific CMI response for IFN-γ secretion (60 ± 14 SFC/106 splenocytes), but not for IL-2.

3.3 Breadth of CMI response in immunized mice

The breadth of HIV-1 transgene specific CMI in both Ad5 naïve and Ad5 immune mice after three immunization with Ad5 [E1−, E2b−]gag or Ad5 [E1−, E2b−]-pol was determined. Fourteen days after the final vaccination splenocytes were stimulated with Gag or Pol PP, respectively. ELISpot analysis was used to determine IFN-γ and IL-2 secretion by splenocytes therefore indicating recognition of that PP. Splenocytes from Ad5 naïve and Ad5 immune mice immunized Ad5 [E1−, E2b−]-gag recognized 2 out of the 4 Gag PP (Figure 3A,B). Splenocytes from naïve mice immunized with Ad5 [E1−, E2b−]-pol recognized 5 out of 5 PP and splenocytes from Ad5 immune mice recognized 3 out of 5 PP for IL-2 (Fig. 3C,D). These data indicate that the Ad5 [E1−, E2b−]-gag and Ad5 [E1−, E2b−]-pol induced a broad range of immune responses that recognized 7 out of 9 PP in naïve mice and 5 out of 9 PP in Ad5 immune mice.

Figure 3
Breadth of transgene specific cellular immunity in Ad5 naïve and hyper immune mice after immunizations with Ad5 [E1−, E2b−]-gag or Ad5 [E1−, E2b−]-pol

3.4 Triad vaccination with Ad5 [E1−, E2b−]-gag, Ad5 [E1−, E2b−]-pol, and Ad5 [E1−, E2b−]-nef

The immune response elicited to the Ad5 [E1−, E2b−] HIV-1 vaccines when administered simultaneously to Ad5 naïve and Ad5 immune mice was evaluated. Mice were immunized three times at two week intervals with 1010 VP each of Ad5 [E1−, E2b−]-gag, Ad5 [E1−, E2b−]-pol, and Ad5 [E1−,E2b−,]-nef. As presented in Figure 5A, immunizations in naïve mice with the triad vaccine induced CMI against Gag (472± 90 SFC/106 IFN-γ secreting splenocytes and 93± 17 SFC/106 IL-2 secreting splenocytes), Pol (8194± 305 SFC/106 IFN-γ secreting splenocytes, 324± 33 SFC/106 IL-2 secreting splenocytes) and Nef (133± 28 SFC/106 IFN-γ secreting splenocytes, no detectable response for IL-2 secretion). Ad5 immune mice immunized with the triad vaccine demonstrated CMI against Gag, Pol and Nef despite the presence of high-titer Ad5 immunity (Figure 4B). These data indicate that the Ad5 [E1−, E2b−] HIV-1 triad vaccine can elicit transgene-specific immune responses in naïve and Ad5 immune mice when administered simultaneously.

Figure 4
Triad vaccination with Ad5 [E1−, E2b−]-gag, Ad5 [E1−, E2b−]-pol, and Ad5 [E1−, E2b−]-nef


As indicated by the Merck STEP trial, a vaccine comprised of Ad5 vectors must effectively deliver the transgenes despite the presence of Ad5 immunity in the vaccinee. Here we evaluated the efficacy of a novel Ad5 [E1−, E2b−,] vector expressing HIV-1 Gag, Pol and Nef proteins to induce CMI responses in both Ad5 naïve and Ad5 immune animals. We report that Ad5 [E1−, E2b−]-gag, Ad5 [E1−, E2b−]-pol, and Ad5 [E1−, E2b−,]-nef vaccines induced INF-γ secretion in not only Ad5 naïve but more importantly in Ad5 immune mice. Ad5 [E1−, E2b−]gag and Ad5 [E1−]-pol also induced IL-2 secretion in Ad5 naïve and Ad5 immune mice, demonstrating HIV-1 specific CMI in vaccinated mice. The propensity of the Ad5 [E1−, E2b−] vector to overcome the barrier of preexisting Ad5 immunity may be linked to dramatic reduction of expression of Ad5 late genes (16). Reduction of Ad5 late gene expression may induce a lower and slower memory immune response against the vector, allowing longer and stable vectored gene expression.

We also demonstrated that Ad5 [E1−, E2b−]-gag and Ad5 [E1−, E2b−]-pol induce a wide breadth CMI response. Previous reports showed that individuals with untreated chronic HIV-1 infection patients recognized significantly more protein subunits (median, 9 peptide pools out of total 100 pools) than individuals with treated acute infection (median, 4 peptide pools) screened with a total of 100 peptide pools spanning entire HIV-1 genome (22). Others have reported that there is a negative correlation between viral load and IFN-γ production of HIV-1-specific T cells using fewer epitopes or HIV-1 proteins (2325). The broadening of the CMI repertoire may prevent viral escape during acute and early infection, thus resulting in a more efficacious control of viral replication. The capacity of Ad5 [E1−, E2b−] vaccine to induce broad CMI recognition of HIV-1 protein subunits will play an critical role in HIV-1 viral load control and may have important implication for HIV-1 vaccine design. To understand the mechanism of immune responses induced by the Ad5 [E1−, E2b−] vaccine platform, future studies, such as the investigation of detailed phenotypic, functional determinants and the “quality” of HIV-1-specific CMI responses are needed and are underway (2628).

Figure 1
CMI responses to immunizations in Ad5 naïve mice
Figure 2
CMI response to immunizations in Ad5 immune mice


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

5.0 References

1. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189:991–998. [PMC free article] [PubMed]
2. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999;283:857–860. [PubMed]
3. Gómez-Román VR, Robert-Guroff M. Adenoviruses as vectors for HIV vaccines. AIDS Rev. 2003;5:178–185. [PubMed]
4. Robinson HL. New hope for an AIDS vaccine. Nat Rev Immunol. 2002;2:239–250. [PubMed]
5. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med. 1996;184:1879–1890. [PMC free article] [PubMed]
6. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol. 1998;72:4212–4223. [PMC free article] [PubMed]
7. Kirk CJ, Mulé JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther. 2000;11:797–806. [PubMed]
8. Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol. 2003;77:6305–6313. [PMC free article] [PubMed]
9. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol. 2003;77:799–803. [PMC free article] [PubMed]
10. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415:331–335. [PubMed]
11. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006;194:1638–1649. [PMC free article] [PubMed]
12. Fitzgerald JC, Gao GP, Reyes-Sandoval A, et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol. 2003;170(3):1416–22. [PubMed]
13. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med. 2004;55:355–372. [PubMed]
14. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol. 2003;77:799–803. [PMC free article] [PubMed]
15. Xiang Z, Gao G, Reyes-Sandoval A, et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol. 2002;76:2667–2675. [PMC free article] [PubMed]
16. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol. 1998;72:926–933. [PMC free article] [PubMed]
17. Hauser MA, Amalfitano A, Kumar-Singh R, Hauschka SD, Chamberlain JS. Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy. Neuromuscul Disord. 1997;7:277–283. [PubMed]
18. Hu H, Serra D, Amalfitano A. Persistence of an [E1−, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum Gene Ther. 1999;10:355–364. [PubMed]
19. Hodges BL, Serra D, Hu H, Begy CA, Chamberlain JS, Amalfitano A. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. J Gene Med. 2000;2:250–259. [PubMed]
20. Everett RS, Hodges BL, Ding EY, Xu F, Serra D, Amalfitano A. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors. Hum Gene Ther. 2003;14:1715–1726. [PubMed]
21. Schaack J. Induction and inhibition of innate inflammatory responses by adenovirus early region proteins. Viral Immunol. 2005;18:79–88. [PubMed]
22. Addo MM, Yu XG, Rathod A, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol. 2003;77:2081–2092. [PMC free article] [PubMed]
23. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998;279:2103–2106. [PubMed]
24. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol. 2002;76:2298–2305. [PMC free article] [PubMed]
25. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379–385. [PubMed]
26. Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001;410:106–111. [PubMed]
27. Rowland-Jones SL, Pinheiro S, Kaul R, et al. How important is the ‘quality’ of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection? Immunol Lett. 2001;79:15–20. [PubMed]
28. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999;283:857–860. [PubMed]